Estimating prevalence of early symptomatic Alzheimer's disease in the United States.

ABSTRACT:

Introduction

Understanding the prevalence of treatment-eligible Alzheimer's disease (AD) is crucial for policy planning.

Methods

We used a comprehensive literature review and population cascade approach to estimate the number of amyloid-positive, clinically diagnosed patients with mild cognitive impairment (MCI) or mild dementia due to AD in the United States.

Results

An estimated 666,646 individuals were identified as having MCI due to AD (range: 351,926-1,227,776) and 620,850 individuals as having mild dementia due to AD (range: 445,082-820,339). In a US population of 76 million individuals aged 60 or older in 2021, the estimates of MCI and mild dementia due to AD increased with age.

Conclusions

As earlier diagnosis of AD and new disease-modifying treatments

SUBMITTER: Spargo D 

PROVIDER: S-EPMC10682565 | biostudies-literature | 2023 Oct-Dec

REPOSITORIES: biostudies-literature